← Eichor
Study identifier: NCT05704166 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients

Condition: Acute Lung Injury · Prevention  ·  Sponsor: Fujian Medical University Union Hospital

PhasePhase 2
Planned participants214
Who can joinFemale, 18 Years to 75 Years
Healthy volunteersNo

About this study

The incidence of chest CT manifestations of lung injury after radiotherapy for breast cancer is more than 50%. Although the prognosis and quality of life of patients are rarely affected, it is still necessary to prevent the occurrence of minor radiation lung injury with the use of more novel drugs and subsequent salvage treatment may aggravate the radiation injury. This study intends to conduct a randomized, double-blind, single-center clinical study of pirfenidone versus placebo in the prevention of acute radiation induced lung injury after breast cancer surgery

This description comes directly from the study's public registry record.

Talk to the study team

Yong Yang, Doctor  ·  18813019084  ·  dr_yangyong1983@163.com

Daxin Huang, Master  ·  13655913399  ·  1660579075@qq.com

Always discuss trial participation with your own doctor first.

Locations (1)

Fujian Medical University Union HospitalFuzhou, Fujian, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05704166